Dose estimate of inhaled hafnium tritide using the ICRP 66 lung model.
Metal tritide is widely used for research, purification, compression, and storage of tritium. The current understanding of metal tritide and its radiation dosimetry for internal exposure is limited, and ICRP publications do not provide the tritium dosimetry for hafnium tritide. The current radiation protection guidelines for metal tritide particles (including hafnium tritide) are based on the assumption that their biological behavior is similar to tritiated water, which is completely absorbed by the body. However, the solubility of metal tritide particles depends on the chemical form of the material. The biological half-live of hafnium tritide particles and the dosimetry of an inhalation exposure to those particles could be quite different from tritiated water. This paper describes experiments on the dissolution rate of hafnium tritide particles in a simulated lung fluid. The results showed that less than 1% of the tritium was dissolved in the simulated lung fluid for hafnium tritide particles after 215 d. The short-term and long-term dissolution half times were 46 and 4.28 x 10(5) d, respectively. This indicates that hafnium tritide is an extremely insoluble material. Self-absorption of beta rays in the hafnium tritide particles was estimated by a numerical method. The dose coefficients were calculated as a function of particle size using in vitro solubility data and a calculated self-absorption factor. The dose coefficient decreased with aerodynamic diameters in the range of 0.25 to 10 microm, mainly because the self-absorption factor decreased with increasing particle size. For a particle 1 microm in aerodynamic diameter, the dose coefficient of a hafnium tritide particle was about 10 times higher than that of tritiated water but was about 1.4 times lower than that calculated by ICRP Publication 71 for Type S tritiated particles. The ICRP estimate did not include a self-absorption factor and thus might have overestimated the dose. This finding has significant implications for current health protection guidelines.
Cheng
Yung-Sung
YS
Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA. ycheng@lrri.org
Zhou
Yue
Y
Wang
Yang-Sheng
YS
Inkret
William C
WC
Wermer
Joseph R
JR
D000396:Air Pollutants, Radioactive / Q000493:pharmacokinetics*; D006195:Hafnium / Q000493:pharmacokinetics*; D006801:Humans; D019570:Inhalation Exposure; D008168:Lung / Q000033:anatomy & histology / Q000502:physiology / Q000528:radiation effects*; D008854:Microscopy, Electron; D008954:Models, Biological; D010316:Particle Size; D011829:Radiation Dosage; D011835:Radiation Protection; D011874:Radiometry; D012995:Solubility; D014316:Tritium / Q000493:pharmacokinetics*
D000396:Air Pollutants, Radioactive; C458119:hafnium tritide; D014316:Tritium; D006195:Hafnium